5-Propan-2-yl-1,2-dihydropyrimidine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 5-Propan-2-yl-1,2-dihydropyrimidine
• 英文别名: 5-propan-2-yl-1,2-dihydropyrimidine
• 化学式: C₇H₁₂N₂
• 分子量: 124.18
• InChiKey: CNCWUDHYUGKHTN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  24.4
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• MORPHINAN DERIVATIVE
  申请人：The Kitasato Institute

  公开号：EP2774926A1

  公开（公告）日：2014-09-10

  A morphinan derivative represented by the following general formula (I): (in the formula, R1 represents hydrogen, C1-6 alkyl, cycloalkylalkyl (the cycloalkyl moiety has 3 to 6 carbon atoms, and the alkylene moiety has 1 to 5 carbon atoms), aralkyl (the aryl moiety has 6 to 10 carbon atoms, and the alkylene moiety has 1 to 5 carbon atoms) and the like, R2 represents hydrogen, C1-6 alkyl, C3-6 cycloalkyl, C6-10 aryl, aralkyl (the aryl moiety has 6 to 10 carbon atoms, and the alkylene moiety has 1 to 5 carbon atoms) and the like, R3, R4 and R5 represent hydrogen, hydroxy, carbamoyl, C1-6 alkoxy, C6-10 aryloxy and the like, R6a, R6b, R7, R8, R9, and R10 represent hydrogen and the like, X represents O or CH2, and Y represents C=O, SO2, an atomic bond and the like), or an acid addition salt thereof is used as an analgesic.

  由以下通式 (I) 代表的吗啡南衍生物： (式中，R1 代表氢、C1-6 烷基、环烷基（环烷基有 3 至 6 个碳原子，亚烷基有 1 至 5 个碳原子）、芳烷基（芳基有 6 至 10 个碳原子，亚烷基有 1 至 5 个碳原子）等、 R2 代表氢、C1-6 烷基、C3-6 环烷基、C6-10 芳基、芳烷基（芳基有 6 至 10 个碳原子，亚烷基有 1 至 5 个碳原子）等、 R3、R4 和 R5 代表氢、羟基、氨基甲酰基、C1-6 烷氧基、C6-10 芳氧基等、 R6a、R6b、R7、R8、R9 和 R10 代表氢等、 X 代表 O 或 CH2，以及 Y 代表 C=O、SO2、原子键等）或其酸加成盐用作镇痛剂。
• ORGANIC TRANSISTOR, COMPOUND, ORGANIC SEMICONDUCTOR MATERIAL FOR NON-LIGHT-EMITTING ORGANIC SEMICONDUCTOR DEVICES, MATERIAL FOR ORGANIC TRANSISTORS, COATING SOLUTION FOR NON-LIGHT-EMITTING ORGANIC SEMICONDUCTOR DEVICES, AND ORGANIC SEMICONDUCTOR FILM FOR NON-LIGHT-EMITTING ORGANIC SEMICONDUCTOR DEVICES
  申请人：Fujifilm Corporation

  公开号：EP3101704A1

  公开（公告）日：2016-12-07

  Provided are an organic transistor having high carrier mobility that contains a compound represented by Formula (1-1) or (1-2) in a semiconductor active layer; a compound; an organic semiconductor material for a non-light-emitting organic semiconductor device; a material for an organic transistor; a coating solution for a non-light-emitting organic semiconductor device; and an organic semiconductor film for a non-light-emitting organic semiconductor device (X1 represents S, O, Se, or NR9; X2 represents S, O, or Se; each of R1 to R9 represents a hydrogen atom or a substituent; at least one of R1, R2, R3, R4 R5, R6, R7, R8, and R9 represents -L-R; each of R9 to R17 represents a hydrogen atom or a substituent; at least one of R9 R10, R11, R12, R13, R14, R15, R16, and R17 represents -L-R; L represents a specific divalent linking group; and R represents an alkyl group, a cyano group, a vinyl group, an ethynyl group, an oxyethylene group, an oligo-oxyethylene group, a siloxane group, an oligosiloxane group, or a trialkylsilyl group).

  本发明提供了一种具有高载流子迁移率的有机晶体管，该晶体管在半导体有源层中含有式(1-1)或式(1-2)代表的化合物；一种化合物；一种用于非发光有机半导体器件的有机半导体材料；一种用于有机晶体管的材料；一种用于非发光有机半导体器件的涂层溶液；以及一种用于非发光有机半导体器件的有机半导体薄膜（X1代表S、O、Se或NR9；X2代表S、O或Se；R1至R9中的每一个代表氢原子或取代基；R1、R2、R3、R4、R5、R6、R7、R8和R9中的至少一个代表-L-R；R9至R17中的每一个代表氢原子或取代基；R9、R10、R11、R12、R13、R14、R15、R16和R17中的至少一个代表-L-R；L代表特定的二价连接基团；R代表烷基、氰基、乙烯基、乙炔基、氧乙烯基、低聚氧乙烯基、硅氧烷基、低聚硅氧烷基或三烷基硅烷基）。
• TYK2 INHIBITORS AND USES THEREOF
  申请人：Nimbus Lakshmi, Inc.

  公开号：EP3848370A2

  公开（公告）日：2021-07-14

  The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of TYK2, and the treatment of TYK2-mediated disorders.

  本发明提供了用于抑制 TYK2 和治疗 TYK2 介导的疾病的化合物、其组合物和使用方法。
• Beta-lactamase inhibitors
  申请人：VenatoRx Pharmaceuticals, Inc.

  公开号：US11046716B2

  公开（公告）日：2021-06-29

  Described herein are compounds and compositions that modulate the activity of beta-lactamases. In some embodiments, the compounds described herein inhibit beta-lactamase. In certain embodiments, the compounds described herein are useful in the treatment of bacterial infections.

  本文描述了调节β-内酰胺酶活性的化合物和组合物。在某些实施方案中，本文所述化合物可抑制β-内酰胺酶。在某些实施方案中，本文所述化合物可用于治疗细菌感染。
• BETA-LACTAMASE INHIBITORS
  申请人：VenatoRx Pharmaceuticals, Inc.

  公开号：US20200055877A1

  公开（公告）日：2020-02-20

  Described herein are compounds and compositions that modulate the activity of beta-lactamases. In some embodiments, the compounds described herein inhibit beta-lactamase. In certain embodiments, the compounds described herein are useful in the treatment of bacterial infections.